An Analysis Of Risk Factors Of Liver Metastases From Non-small Cell Lung Cancer And A Comparison Of Different Treatments For It

Objective To explore the risk factors of liver metastases from non-small cell lung cancer(NSCLC);to compare the advantages and limits of surgery,chemotherapy and chemotherapy combined with transcatheter arterial chemoembolization(TACE)in treating the liver metastases from NSCLC and to compare the advantages and limits of doxorubicin-eluting bead(DEB)and lipiodol with TACE.Methods We reviewed literature to find potential risk factors that could affect liver metastases from NSCLC.Next,they were investigated using the chi-square test and logistic regression analysis.Also,Kplan-Meier survival curve analysis was used to compare the three kinds of treatments.At last,we explore the efficacy/safety of DEB and lipiodol.Results Chi-square test and logistic regression analysis suggested that no history of hepatitis B(P <0.001),adenocarcinoma(P=0.004)and stage III(P <0.001)were independent prognostic factors.The efficiency rate was 100% for surgery,31% for chemotherapy and 65% for chemotherapy combined with TACE(CCT),respectively(?2=10.037,P=0.002).The median PFS was 6.3 months for surgery,5.9 months for chemotherapy and 7.9 months for CCT,respectively(surgery vs chemotherapy: ?2=0.540,P=0.462;CCT vs chemotherapy: ?2=2.561,P=0.001;CCT vs surgery: ?2=3.762,P=0.007).The 1month effective rate of DEB,70%,was significantly higher than that of lipiodol,52%(?2=8.238,P = 0.003).The 4 month effective rate of DEB,50%,was significantly higher than that of lipiodol,25%(?2= 25.128,P = 0.015).The incidence of serious adverse reactions of DEB was significantly lower than that of lipiodol.Conclusions No history of hepatitis B,adenocarcinoma and stage III are risk factors of liver metastases from NSCLC.CCT may bring more PFS benefits compared with surgery and chemotherapy for patients with liver metastases from NSCLC.The DEB is superior to the conventional lipiodol for TACE.